Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 3
1947 7
1948 5
1949 2
1950 7
1951 5
1952 6
1953 4
1954 1
1955 1
1956 4
1957 3
1958 1
1959 4
1960 3
1961 5
1962 2
1963 5
1964 9
1965 1
1971 3
1972 31
1973 61
1974 126
1975 205
1976 276
1977 348
1978 462
1979 475
1980 479
1981 539
1982 641
1983 819
1984 918
1985 978
1986 1073
1987 1071
1988 1120
1989 1253
1990 1356
1991 1341
1992 1320
1993 1360
1994 1415
1995 1265
1996 1300
1997 1370
1998 1365
1999 1437
2000 1482
2001 1584
2002 1606
2003 1642
2004 1746
2005 1881
2006 2052
2007 2068
2008 2061
2009 2152
2010 2584
2011 2789
2012 3029
2013 3210
2014 3428
2015 3696
2016 3761
2017 3906
2018 4167
2019 4226
2020 4418
2021 4222
2022 3954
2023 3668
2024 3702
2025 4085
2026 271

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93,378 results

Results by year

Filters applied: . Clear all
Page 1
An overview of doxorubicin formulations in cancer therapy.
Rivankar S. Rivankar S. J Cancer Res Ther. 2014 Oct-Dec;10(4):853-8. doi: 10.4103/0973-1482.139267. J Cancer Res Ther. 2014. PMID: 25579518 Free article. Review.
The first liposomal encapsulated anticancer drug which received clinical approval against malignancies including solid tumours, transplantable leukemias and lymphomas was Doxorubicin HCl. This review is aimed at providing an overview of doxorubicin in cancer therapy …
The first liposomal encapsulated anticancer drug which received clinical approval against malignancies including solid tumours, transplantab …
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Balleyguier C, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bardet A, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Archambaud B, Duffaud F; French Sarcoma Group. Pautier P, et al. Lancet Oncol. 2022 Aug;23(8):1044-1054. doi: 10.1016/S1470-2045(22)00380-1. Epub 2022 Jul 11. Lancet Oncol. 2022. PMID: 35835135 Free article. Clinical Trial.
FINDINGS: Between Jan 18, 2017, and March 21, 2019, 150 patients were enrolled (67 with uterine leiomyosarcomas and 83 with soft tissue leiomyosarcomas) and included in the intention-to-treat population: 76 in the doxorubicin alone group and 74 in the doxorubicin pl …
FINDINGS: Between Jan 18, 2017, and March 21, 2019, 150 patients were enrolled (67 with uterine leiomyosarcomas and 83 with soft tissue leio …
Clinical pharmacokinetics of doxorubicin.
Speth PA, van Hoesel QG, Haanen C. Speth PA, et al. Clin Pharmacokinet. 1988 Jul;15(1):15-31. doi: 10.2165/00003088-198815010-00002. Clin Pharmacokinet. 1988. PMID: 3042244 Review.
Doxorubicin has been administered as frequent (weekly) low doses, single high doses, and as a continuous infusion. ...Clinical trials large enough to study optimal, and possibly individualised, doxorubicin chemotherapy need to be performed. This review summarises ph …
Doxorubicin has been administered as frequent (weekly) low doses, single high doses, and as a continuous infusion. ...Clinical trials …
Liposomal doxorubicin.
Tardi PG, Boman NL, Cullis PR. Tardi PG, et al. J Drug Target. 1996;4(3):129-40. doi: 10.3109/10611869609015970. J Drug Target. 1996. PMID: 8959485 Review.
Doxorubicin is a potent antineoplastic agent with activity against numerous human cancers. ...The therapeutic benefits of liposomal doxorubicin will therefore depend on these physical characteristics. Here we review the toxicity and efficacy of liposomal doxorubi …
Doxorubicin is a potent antineoplastic agent with activity against numerous human cancers. ...The therapeutic benefits of liposomal …
Doxorubicin Action on Mitochondria: Relevance to Osteosarcoma Therapy?
Armstrong J, Dass CR. Armstrong J, et al. Curr Drug Targets. 2018;19(5):432-438. doi: 10.2174/1389450116666150416115852. Curr Drug Targets. 2018. PMID: 25882220 Review.
Cancer chemotherapeutics such as the anthracycline doxorubicin perturb mitochondrial structure and function in tumour cells, as evidenced in osteosarcoma, for which doxorubicin is used clinically as frontline therapy. This same mechanism of cell inhibition is also p …
Cancer chemotherapeutics such as the anthracycline doxorubicin perturb mitochondrial structure and function in tumour cells, as evide …
A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer.
Bisht A, Avinash D, Sahu KK, Patel P, Das Gupta G, Kurmi BD. Bisht A, et al. Drug Deliv Transl Res. 2025 Jan;15(1):102-133. doi: 10.1007/s13346-024-01648-0. Epub 2024 Jun 17. Drug Deliv Transl Res. 2025. PMID: 38884850 Review.
Nanoformulations show promise in enhancing doxorubicin's effectiveness by improving drug delivery, reducing side effects, and overcoming drug resistance. ...Understanding these different aspects is crucial in optimizing doxorubicin's use and improving …
Nanoformulations show promise in enhancing doxorubicin's effectiveness by improving drug delivery, reducing side effects, and …
Doxorubicin.
Schulmeister L. Schulmeister L. Clin J Oncol Nurs. 1998 Jul;2(3):115-6. Clin J Oncol Nurs. 1998. PMID: 10232157 No abstract available.
Molecular mechanism of doxorubicin-induced cardiomyopathy - An update.
Renu K, V G A, P B TP, Arunachalam S. Renu K, et al. Eur J Pharmacol. 2018 Jan 5;818:241-253. doi: 10.1016/j.ejphar.2017.10.043. Epub 2017 Oct 23. Eur J Pharmacol. 2018. PMID: 29074412 Review.
The mechanism of doxorubicin is intercalated with the DNA and inhibits topoisomerase 2. There are various signalling mechanisms involved in doxorubicin cardiotoxicity. First and foremost, the doxorubicin-induced cardiotoxicity is due to oxidative stress. Card …
The mechanism of doxorubicin is intercalated with the DNA and inhibits topoisomerase 2. There are various signalling mechanisms invol …
Doxorubicin, a DNA intercalator, inhibits transcription elongation.
Tempel M, Green K, Prajapati D, Duaqui A, Norouzi M, Sattarifard H, Ashraf A, Wu E, Zovoilis A, Lakowski T, Davie JR. Tempel M, et al. Biochem Cell Biol. 2025 Jan 1;103:1-12. doi: 10.1139/bcb-2024-0264. Biochem Cell Biol. 2025. PMID: 39951687 Free article.
Doxorubicin was reported to result in loss of histone H3 trimethylated lysine 4 (H3K4me3). To further explore doxorubicin's mechanism of action, we determined the genomic location of the binding sites of doxorubicin in leukemic cells. ...
Doxorubicin was reported to result in loss of histone H3 trimethylated lysine 4 (H3K4me3). To further explore doxorubicin's …
Dapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity.
Ulusan S, Gülle K, Peynirci A, Sevimli M, Karaibrahimoglu A, Kuyumcu MS. Ulusan S, et al. Anatol J Cardiol. 2023 Jun;27(6):339-347. doi: 10.14744/AnatolJCardiol.2023.2825. Anatol J Cardiol. 2023. PMID: 37257007 Free PMC article.
METHODS: A total of 40 male Wistar albino rats were divided into 4 groups consisting of 10 each (control = 10, dapagliflozin = 10, doxorubicin = 10, doxorubicin + dapagliflozin = 10). Meanwhile, doxorubicin and doxorubicin + dapagliflozin groups receiv …
METHODS: A total of 40 male Wistar albino rats were divided into 4 groups consisting of 10 each (control = 10, dapagliflozin = 10, doxoru …
93,378 results
You have reached the last available page of results. Please see the User Guide for more information.